This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Pathogenesis of type I diabbetes (IDDM)

Authoring team

The pathogenesis of IDDM is one of slow, progressive immunological destruction of the beta cell mass by antigen specific cytotoxic T-lymphocytes augmented by cytokine release from macrophages and NK-Cells.

The loss of beta cells is slow and one can detect progressive glucose intolerance over time. Symptomatic diabetes mellitus and insulin dependence occurs only when the beta cell mass is reduced to 10% of normal and often presents acutely as a result of an increase in insulin resistance associated with puberty or concurrent infection.

Although the humoral immune response is not thought to play an important role in the destruction of beta cells a number of autoantibodies have been identified and are of some predictive significance:

  • cytoplasmic islet cell antibodies (ICA) are present in approximately 80% of newly diagnosed IDDM patients

  • family members of IDDM patients who have islet cell antibodies are at an increased risk of developing diabetes themselves and furthermore the magnitude of this risk is related to the titres and persistence of their ICA response

  • glutamic acid decarboxylase (GAD) autoantibodies have also been identified and shown to be present before IDDM is diagnosed

  • anti-insulin antibodies have also been studied

  • the presence of ICA and anti-insulin antibodies is highly predictive for IDDM

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.